Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.64 EUR | +1.44% | -5.53% | +31.78% |
17/04 | OSE: licensing agreement with AbbVie enters into force | CF |
17/04 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Evolution of the average Target Price on OSE Immunotherapeutics
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
EPS Revisions
- Stock Market
- Equities
- OSE Stock
- Consensus OSE Immunotherapeutics